Sulindac
Code | Size | Price |
---|
TAR-T0459-50mg | 50mg | £103.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T0459-100mg | 100mg | £108.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T0459-1mL | 1 mL * 10 mM (in DMSO) | £111.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T0459-200mg | 200mg | £124.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T0459-500mg | 500mg | £148.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Images
Documents
Further Information
Bioactivity:
Sulindac is a sulfinylindene derivative prodrug with potential antineoplastic activity. Converted in vivo to an active metabolite, sulindac, a nonsteroidal anti-inflammatory drug (NSAID), blocks cyclic guanosine monophosphate-phosphodiesterase (cGMP-PDE), an enzyme that inhibits the normal apoptosis signal pathway; this inhibition permits the apoptotic signal pathway to proceed unopposed, resulting in apoptotic cell death.
CAS:
38194-50-2
Formula:
C20H17FO3S
Molecular Weight:
356.41
Pathway:
Neuroscience; Immunology/Inflammation; Autophagy
Purity:
0.9949
SMILES:
CC1=C(CC(O)=O)c2cc(F)ccc2C1=C/c1ccc(cc1)S(C)=O
Target:
COX; Autophagy
References
1. Yamamoto Y, et al. J Biol Chem,1999, 274(38), 27307-27314.
2. Piazza GA, et al. Cancer Res,1995, 55(14), 3110-3116.
3. Boon EM, et al. Br J Cancer. 2004 Jan 12;90(1):224-9.
4. Boolbol SK, et al. Cancer Res,1996, 56(11), 2556-2560.
5. Chiu CH, et al. Cancer Res,1997, 57(19), 4267-4273.
6. Gong EY, et al. Combined treatment with vitamin C and sulindac synergistically induces p53- and ROS-dependent apoptosis in human colon cancer cells. Toxicol Lett. 2016 Sep 6;258:126-133.
7. Cha BK, et al. Celecoxib and sulindac inhibit TGF-?1-induced epithelial-mesenchymal transition and suppress lung cancer migration and invasion via downregulation of sirtuin 1. Oncotarget. 2016 Aug 30;7(35):57213-57227.